Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02238210
Recruitment Status : Completed
First Posted : September 12, 2014
Last Update Posted : September 12, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to determine the safety of Atrovent Nasal Spray 0.06% in pediatric patients (ages 2-5 years) with symptoms of rhinorrhea associated with a naturally occurring common cold or from symptoms of rhinorrhea associated with allergies

Condition or disease Intervention/treatment Phase
Cold Drug: Atrovent® Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 230 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV Safety Trial in Pediatric Patients (Ages 2-5) With Rhinorrhea Associated With a Common Cold or Allergy
Study Start Date : December 2002
Actual Primary Completion Date : May 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy Common Cold

Arm Intervention/treatment
Experimental: Atrovent® - common cold group
Treatment duration for common cold group - three time daily for 4 days
Drug: Atrovent®
Experimental: Experimental: Atrovent® - allergy group
Treatment duration for allergy group - three time daily for 14 days
Drug: Atrovent®



Primary Outcome Measures :
  1. Patient's parent/legal guardian global assessment - common cold group [ Time Frame: Day 4 ]
  2. Number of patients with adverse events [ Time Frame: up to 21 days ]
  3. Patient's parent/legal guardian global assessment - allergy group [ Time Frame: Day 14 ]

Secondary Outcome Measures :
  1. Patient's parent/legal guardian daily assessment of rhinorrhea (runny nose) rated on 5-point scale - common cold group [ Time Frame: Day 4 ]
    daily assessment by e-diary

  2. Patient's parent/legal guardian daily assessment of nasal congestion (stuffy nose) rated on 5-point scale - common cold group [ Time Frame: Day 4 ]
    daily assessment by e-diary

  3. Patient's parent/legal guardian daily assessment of sneezing rated on 5-point scale - common cold group [ Time Frame: Day 4 ]
    daily assessment by e-diary

  4. Number of patients with clinically findings in nasal and otoscopic examination - common cold group [ Time Frame: up to day 4 ]
  5. Patient's parent/legal guardian daily assessment of rhinorrhea (runny nose) rated on 5-point scale - allergy group [ Time Frame: Day 14 ]
    daily assessment by e-diary

  6. Patient's parent/legal guardian daily assessment of nasal congestion (stuffy nose) rated on 5-point scale - allergy group [ Time Frame: Day 14 ]
    daily assessment by e-diary

  7. Patient's parent/legal guardian daily assessment of sneezing rated on 5-point scale - allergy group [ Time Frame: Day 14 ]
    daily assessment by e-diary

  8. Number of patients with clinically findings in nasal and otoscopic examination - allergy group [ Time Frame: up to day 14 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for patients with common cold

  • Male or female at least 2 but not older than 5 years of age at screening
  • Have a diagnosis of a common cold defined as presence of acute onset of rhinorrhea (within 48 hours of screening visit) and at least 1 of the following:

    • Presence of swollen nasal membranes characteristic of a common cold on examination at screening
    • Presence of fever up to 102°F (oral or equivalent) within 48 hours of visit (may be taken at home/away from the clinic) or at time of screening
  • Capability of parent/legal guardian to read and understand the informed consent, record trial diary information, administer trial drug and read and understand trial assessment questionnaire

Inclusion Criteria for patients with allergies

  • Male or female at least 2 but not older than 5 year of age
  • Have a diagnosis of seasonal or perennial allergic rhinitis defined as having both of the following:

    • Positive skin or Radioallergosorbent test (RAST) test to a relevant allergen within 12 months of screening or at the screening visit. For the purpose of this trial a positive skin test is defined as wheal diameter that is at least 3 mm greater than the negative control
    • Positive prior history for atopy with nasal symptoms associated with expose to allergens
  • Symptoms associated with rhinorrhea for at least 48 hours prior to the screening visit
  • Capability of parent/legal guardian to read and understand the informed consent, record trial diary information, administer trial drug and read and understand trial assessment questionnaire

General Exclusion Criteria for both common cold and allergy

  • Significant cardiovascular, renal, hepatic, endocrine, metabolic, neurologic or other systemic disease. A significant disease was defined as one which, in the opinion of the Investigator, either put the patient at risk because of participation in the trial or influenced the results of the trial or the patient's ability to participate in the trial
  • Presence of rales or rhonchi suggestive of a lower respiratory tract infection
  • An oral (or equivalent) temperature higher than 102°F
  • Presence of otitis media
  • Be initiating or advancing immunotherapy regimen during the course of this trial. Patients receiving a maintenance dose of immunotherapy are eligible
  • Known intolerance to anticholinergics of hypersensitivity to benzalkonium chloride
  • Excluded medications prior to Visit 1 and during the trial included:

    1. 24 hours before

      • Over-the-counter decongestants or nasal/ocular cromolyn
    2. 3 days before:

      • Anticholinergics
      • Over-the-counter antihistamines
      • sympathomimetic decongestants
    3. 5 days before:

      • Fexofenadine
      • Loratadine
    4. 7 days before:

      • Cetirizine
      • antihistamines such as Atarax® or doxepin hydrochloride
      • Antidepressants
    5. 14 days before:

      • Intranasal steroids
    6. 28 days before:

      • Steroids (oral and injectable)
      • Leukotriene modifiers (e.g. Accolate®, Singulair®)
      • Other investigational drugs
  • Participation in any trial with an investigational drug within 30 days of the screening visit
  • Nasal obstruction greater than 50% that would prevent deposition of trial drug
  • The parent/legal guardian has a disability or lives in a geographical location that could impair compliance with the protocol or visits to the trial center

Exclusion criteria for patients with a common cold

  • History or perennial allergic rhinitis or seasonal allergic rhinitis (SAR) with allergen in season
  • Positive Streptococcus test

Exclusion criteria for patients with allergies

  • Patients with active infectious rhinitis (common cold) as determined by history and physical
  • Patients with upper or lower respiratory infection at screening

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02238210     History of Changes
Other Study ID Numbers: 244.2503
First Posted: September 12, 2014    Key Record Dates
Last Update Posted: September 12, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Common Cold
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Ipratropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action